Drug intelligence / Profile preview

TNX-2600

Development stage: Preclinical
Lead developer: Tonix Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal, Parenteral

Overview

TNX-2600 is a preclinical COVID-19 vaccine candidate being developed by Tonix Pharmaceuticals in collaboration with Kansas State University. The vaccine utilizes a novel live attenuated bovine parainfluenza virus (BPIV) vector platform. It is specifically designed to stimulate T cell-mediated immunity against SARS-CoV-2, potentially offering a differentiated immunological profile compared to first-generation vaccines that primarily target neutralizing antibodies. Tonix holds an option to license this technology as part of its broader infectious disease and vaccine development pipeline.

Beyond the preview

Go deeper on TNX-2600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-2600.

Explore the full profile